Quintiles Transitional Holdings Inc. (NYSE:Q)‘s stock had its “hold” rating reaffirmed by stock analysts at SunTrust Banks, Inc. in a research report issued to clients and investors on Friday. They currently have a $114.00 price target on the medical research company’s stock. SunTrust Banks, Inc.’s target price points to a potential upside of 5.54% from the stock’s current price. SunTrust Banks also issued estimates for Quintiles Transitional Holdings’ FY2017 earnings at $4.60 EPS, FY2018 earnings at $5.48 EPS and FY2019 earnings at $6.48 EPS.
Several other research analysts also recently issued reports on Q. Robert W. Baird upgraded Quintiles Transitional Holdings from an “underperform” rating to a “neutral” rating and lifted their price objective for the stock from $76.00 to $93.00 in a research report on Friday, July 7th. Barclays PLC reaffirmed an “overweight” rating and issued a $98.00 target price (up from $90.00) on shares of Quintiles Transitional Holdings in a research note on Monday, July 17th. Zacks Investment Research raised shares of Quintiles Transitional Holdings from a “hold” rating to a “buy” rating and set a $101.00 target price for the company in a research note on Thursday, July 27th. William Blair raised shares of Quintiles Transitional Holdings from a “market perform” rating to an “outperform” rating and lifted their target price for the stock from $70.10 to $93.42 in a research note on Friday, August 4th. Finally, Jefferies Group LLC reaffirmed a “hold” rating and issued a $94.00 target price on shares of Quintiles Transitional Holdings in a research note on Friday, August 4th. Ten research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Quintiles Transitional Holdings presently has a consensus rating of “Buy” and a consensus target price of $102.33.
Shares of Quintiles Transitional Holdings (NYSE:Q) opened at $108.02 on Friday. The company has a debt-to-equity ratio of 1.29, a quick ratio of 1.23 and a current ratio of 1.22. The stock has a market cap of $22.67 billion, a PE ratio of 24.50, a P/E/G ratio of 1.78 and a beta of 0.65.
Quintiles Transitional Holdings (NYSE:Q) last posted its quarterly earnings results on Thursday, October 26th. The medical research company reported $1.19 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.14 by $0.05. Quintiles Transitional Holdings had a net margin of 0.58% and a return on equity of 12.60%. The company had revenue of $2.02 billion during the quarter, compared to the consensus estimate of $2.01 billion. During the same period last year, the firm earned $1.00 EPS. The company’s revenue for the quarter was up 77.6% on a year-over-year basis. research analysts expect that Quintiles Transitional Holdings will post 4.62 EPS for the current year.
In related news, insider Kevin C. Knightly sold 19,339 shares of the business’s stock in a transaction dated Friday, August 25th. The shares were sold at an average price of $99.51, for a total transaction of $1,924,423.89. Following the completion of the sale, the insider now owns 40,650 shares of the company’s stock, valued at approximately $4,045,081.50. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Ari Bousbib sold 92,160 shares of the business’s stock in a transaction dated Monday, August 7th. The shares were sold at an average price of $90.35, for a total transaction of $8,326,656.00. Following the sale, the insider now directly owns 1,082,919 shares of the company’s stock, valued at approximately $97,841,731.65. The disclosure for this sale can be found here. In the last 90 days, insiders sold 14,254,462 shares of company stock worth $1,367,822,566. Company insiders own 6.40% of the company’s stock.
Large investors have recently made changes to their positions in the stock. Fiduciary Trust Co. bought a new stake in shares of Quintiles Transitional Holdings during the 2nd quarter valued at about $105,000. Korea Investment CORP grew its position in shares of Quintiles Transitional Holdings by 142.5% during the 2nd quarter. Korea Investment CORP now owns 1,370 shares of the medical research company’s stock valued at $123,000 after buying an additional 805 shares during the last quarter. GWM Advisors LLC bought a new stake in shares of Quintiles Transitional Holdings during the 2nd quarter valued at about $122,000. Citigroup Inc. grew its position in shares of Quintiles Transitional Holdings by 15.5% during the 2nd quarter. Citigroup Inc. now owns 1,858 shares of the medical research company’s stock valued at $167,000 after buying an additional 250 shares during the last quarter. Finally, Bbva Compass Bancshares Inc. grew its position in Quintiles Transitional Holdings by 4.2% in the 2nd quarter. Bbva Compass Bancshares Inc. now owns 2,204 shares of the medical research company’s stock worth $197,000 after purchasing an additional 88 shares during the last quarter. 93.03% of the stock is owned by institutional investors and hedge funds.
About Quintiles Transitional Holdings
Quintiles IMS Holdings, Inc, formerly Quintiles Transnational Holdings Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.
What are top analysts saying about Quintiles Transitional Holdings Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Quintiles Transitional Holdings Inc. and related companies.